このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HIV 感染児における結核治療決定アルゴリズムの検証

TB-Speed HIV is a prospective multicentre management study evaluating the safety and feasibility of the recently proposed PAANTHER TB treatment decision algorithm for HIV-infected children with presumptive TB. It will be conducted in four countries with high and very high TB (Tuberculosis) incidence (Côte d'Ivoire, Uganda, Mozambique, and Zambia) which have not participated in the study that developed the PAANTHER algorithm.

調査の概要

詳細な説明

The ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research) study, which enrolled 438 HIV-infected children of median age 7.3 (IQR: 3.3 - 9.7) years with presumptive TB in four countries (Burkina Faso, Cameroon, Cambodia, Vietnam) from 2011 to 2014, aimed at developing a diagnostic prediction score and algorithm for TB treatment decision in HIV-infected children. This was the first study developing a TB diagnostic score exclusively in HIV-infected children, using methods recommended for diagnostic prediction models. Based on microbiological, clinical and radiological features, the best scoring system obtained had a sensitivity of 88.6% and specificity of 61.2% when Xpert MTB/RIF was included in the algorithm. The investigators showed previously that mortality is high in children with both confirmed and unconfirmed TB and that initiation of anti-TB treatment, that occurred at a median time of 7 (IQR: 5 - 11) days in the study, led to delayed ART initiation, which is associated to significantly increased mortality. The score, based on easily collected clinical features, chest radiographic features, Xpert MTB/RIF results, and abdominal ultrasonography, could enable same-day TB treatment decision. Abdominal ultrasonography has shown promise for the diagnosis of TB in both HIV-infected adults and children. In the PAANTHER study, it detected abdominal lymphadenopathy in 50% of culture confirmed TB cases and 35% of all confirmed and unconfirmed cases, with a specificity of 85%.

Developed in tertiary research-experienced health facilities, the PAANTHER score could enable standardized treatment decision in HIV-infected children with presumptive TB, and could be recommended for extensive use in secondary and primary healthcare settings where most of these children are seeking care. However, external validation studies are now needed to assess the predictive performance of the PAANTHER diagnostic score on independent datasets.

The PAANTHER TB treatment decision algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. Validation of the algorithm will be performed by evaluating the safety of withholding TB treatment in children not initiated on treatment as per the PAANTHER TB treatment decision algorithm. The safety of this strategy will be carefully assessed through review of safety reports every 4 to 6 months during study conduct by the safety sub-committee of the SAB.

Occurrence of algorithm failures in terms of missed TB cases (TB cases subsequently detected among untreated cases, i.e. false negatives) and cases with unlikely TB among those initiated on TB treatment as per the algorithm (cases not secondarily validated as confirmed or unconfirmed TB cases by the expert committee, i.e. false positives) will enable to estimate the negative and positive predictive values of the algorithm.

A centralized international Expert Committee will clinically review and validate TB diagnosis in children. This will enable assessment of the added value of new markers (MLR and CRP) and, if need be, to propose a new version of the score based on an optimised predicted probability.

The TB-Speed HIV study will be implemented in 7 tertiary healthcare level hospitals in capital cities of Côte d'Ivoire, Uganda, Mozambique, and Zambia. A total of 550 HIV-infected children (aged < 15 years) with clinically suspected TB (presumptive TB) will be enrolled, using standard entry criteria. The inclusion period will last until all sites have reached the expected number of children enrolled.

研究の種類

介入

入学 (実際)

278

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Mbarara、ウガンダ
        • Mbarara Regional Hospital
      • Abidjan、コートジボワール
        • Cocody University Teaching Hospital
      • Abidjan、コートジボワール
        • Treichville University Teaching Hospital
      • Lusaka、ザンビア
        • Lusaka University Teaching Hospital
      • Ndola、ザンビア
        • Arthur Davidson Children Hospital
      • Maputo、モザンビーク
        • José Macamo General Hospital
      • Maputo、モザンビーク
        • Maputo Central Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1ヶ月~14年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Children aged 1 month to 14 years

  2. Documented HIV-infection (i.e., confirmed before entry into the study)

  3. Presumptive TB based on at least one criteria among the following:

    1. Persistent cough for more than 2 weeks
    2. Persistent fever for more than 2 weeks
    3. Recent failure to thrive (documented clear deviation from a previous growth trajectory in the last 3 months or Z score weight/age < 2)
    4. Failure of broad spectrum antibiotics for treatment of pneumonia
    5. Suggestive CXR features

    OR

    History of contact with a TB case and any of the symptoms listed under point 3 with a shorter duration (< 2 weeks)

  4. Informed consent signed by parent/guardian

Exclusion Criteria:

Ongoing TB treatment or history of intake of anti-TB drugs in the last 3 months (isoniazid alone or rifampin/isoniazid for preventive therapy is not an exclusion criteria)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:HIV-infected children with presumptive TB

Recruitment will be performed at entry in HIV outpatient/inpatient centres of participating hospitals, as well as during the follow up of HIV-infected children on ART. Children will be first pre-screened for TB by attending clinicians and nurses in the context of routine care based on WHO criteria, i.e. with any one of the following symptoms: poor weight gain, fever, current cough and contact with a TB case. If not routinely performed, this pre-screening step will be reinforced and a screening logbook will be set up (if not already in place) to collect aggregated data on the eligibility criteria assessment process. Children pre-screened positive for TB will be further subjected to the study selection criteria by the study nurses.

The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:

  • history of contact
  • suggestive TB symptoms
  • tachycardia
  • chest radiography
  • abdominal ultrasound
  • Xpert MTB/RIF Ultra.

A score of >100 is highly predictive of TB. In children with a score >100, anti-TB treatment will be initiated immediately. In children with a score of <100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of missed TB cases
時間枠:6 months

Proportion of missed TB cases (false negative cases) in children not initiated on treatment as per the PAANTHER TB treatment decision algorithm

6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
PAANTHER 結核治療決定アルゴリズムの実現可能性 (b): 最終的な結核治療決定までの時間
時間枠:6ヵ月
6ヵ月
死亡率
時間枠:6ヵ月
6ヵ月
ART未経験児のART開始までの時間
時間枠:6ヵ月
6ヵ月
結核治療の成果 (b): 結核治療を受けている子供の結核症状の改善
時間枠:6ヵ月
6ヵ月
Feasibility of the PAANTHER TB treatment decision algorithm (a): Proportion of children with presumptive TB having completed the algorithm.
時間枠:6 months

The algorithm will be considered completed if a decision to initiate TB treatment has been taken at any step of the algorithm or if TB has been excluded after systematic evaluation, and all steps planned in the algorithm have been implemented.

6 months
Proportion of HIV-infected children with unlikely TB among those initiated on treatment as per the PAANTHER TB treatment decision algorithm
時間枠:6 months

Proportion of cases considered as unlikely TB by the Expert Committee in those initiated on treatment as per the PAANTHER TB treatment decision algorithm (false positive)

6 months
Incidence of morbidity
時間枠:6 months

Incidence of morbidity defined as drug-induced toxicity (ART and TB treatment-related), opportunistic infections, and IRIS, with or without TB treatment

6 months
CD4 (absolute count and %) gain
時間枠:6 months

Immunologic evolution at 6 months after enrolment defined as CD4 cells gain (absolute count and %)

6 months
TB treatment outcomes (a): Weight gain at 6 months (absolute value and percentage of body weight)
時間枠:6 months

TB treatment outcome in HIV-infected children initiated on treatment as per the PAANTHER TB treatment decision algorithm defined by weight gain at 6 months (absolute value and percentage of body weight)

6 months
Feasibility of IPT initiation (a): Time to IPT initiation
時間枠:6 months

Time to Isoniazid Preventive Therapy (IPT) initiation in HIV-infected children not initiated on treatment as per the PAANTHER TB treatment decision algorithm (a)

6 months
Feasibility of IPT initiation (b): Proportion of children initiated on IPT
時間枠:6 months

Proportion of children initiated on IPT in HIV-infected children not initiated on treatment as per the PAANTHER TB treatment decision algorithm (b)

6 months
Performance of the Monocyte-to-Lymphocyte Ratio and the C-reactive protein and their potential added value in the PAANTHER score and algorithm to detect TB
時間枠:6 months

Discrimination (area under the receiver-operating-characteristic curves [AUROC]) and calibration measures of the PAANTHER prediction model including or not MLR and CRP, against the TB composite reference standard as defined by the Expert Committee

6 months
Proportion of NPAs (or sputum) and stool samples with mycobacterium tuberculosis (MTB) detected using Ultra
時間枠:6 months

Diagnostic performance of Ultra performed on one NPA and one stool sample against mycobacterial culture performed on standard samples in HIV-infected children

6 months
Proportion of children with NPA and stool samples collected as per study protocol
時間枠:6 months

Feasibility of NPA and stool samples collection in HIV-infected children defined as the proportion of children with NPA and stool samples collected as per study protocol

6 months
Proportion of NPA-related adverse events (AEs)
時間枠:6 months

Safety of NPA collection defined as proportion of AEs (vomiting, nose bleeding, low oxygen saturation, respiratory distress) occurring during NPA

6 months
Discomfort/pain/distress experienced by the child during NPA as assessed by the child
時間枠:Within 3 days of inclusion

Tolerability of NPA collection defined as discomfort/pain/distress experienced by the child during NPA, as assessed by the child using the Wong-Baker face scale (in a subset of children).

Scale range: 0 (no hurt) - 5 (hurts worst)

Within 3 days of inclusion
Discomfort/pain/distress experienced by the child during NPA as assessed by the parents
時間枠:Within 3 days of inclusion

Tolerability of NPA collection defined as discomfort/pain/distress experienced by the child during NPA, as assessed by the parents using the visual analog scale (in a subset of children).

Scale range: 0 (no pain) - 10 (pain as bad as it could possibly be)

Within 3 days of inclusion
Discomfort/pain/distress experienced by the child during NPA as assessed by the nurse
時間枠:Within 3 days of inclusion

Tolerability of NPA collection defined as discomfort/pain/distress experienced by the child during NPA, as assessed by the nurses using the "Face Legs Activity Cry Consolability" behavioral pain scale (in a subset of children).

Total score range: 0 (relaxed and comfortable) - 10 (severe discomfort/pain). Each item of the FLACC scale - Face, Legs, Activity, Cry, Consolability - has 3 possible quotes: 0 or 1 or 2, with a precise description provided to help with the rating. The total score is obtained by adding individual item scores.

Within 3 days of inclusion
Sensitivity
時間枠:6 months

false negative rate, i.e. negative predictive value, and corresponding sensitivity of the PAANTHER algorithm in the different subgroups in terms of age, CD4 counts, nutritional statuses, and timings of ART initiation (on/off ART)

6 months
Positivity
時間枠:6 months

false positiverate, i.e. Positive predictive value, and corresponding positivity of the PAANTHER algorithm in the different subgroups in terms of age, CD4 counts, nutritional statuses, and timings of ART initiation (on/off ART)

6 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Incremental cost-effectiveness ratio (ICER)
時間枠:33 months

Incremental cost-effectiveness ratio (ICER)

33 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Olivier Marcy, MD, PhD、University of Bordeaux, France
  • 主任研究者:Eric Wobudeya, MD, PhD、MU-JHU Care Ltd, Kampala, Uganda
  • 主任研究者:Maryline Bonnet, MD, PhD、Institut de Recherche pour le Développemnt (IRD) Montpellier, France

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年10月2日

一次修了 (実際)

2022年6月20日

研究の完了 (実際)

2022年6月20日

試験登録日

最初に提出

2019年10月1日

QC基準を満たした最初の提出物

2019年10月7日

最初の投稿 (実際)

2019年10月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2025年2月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する